Janux Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Janux Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- JANX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001817713
- EIN
- 82-2289112
Board of directors
-
Alana B. McNulty · DirectorSince 2023
-
David Alan Campbell · Director · President and CEOSince 2023
-
Eric Dobmeier · DirectorSince 2024
- Since 2023
-
Jay Lichter · DirectorSince 2023
-
Natasha Hernday · DirectorSince 2024
- Since 2023
- Since 2023
-
Ronald W. Barrett · DirectorSince 2023
-
Sheila Gujrathi · DirectorSince 2023
-
Vickie L. Capps · DirectorSince 2023
-
Winston Kung · DirectorSince 2023
Chief executives
David Alan Campbell
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
90.5%
-
97.7%
Board connections
7 of this board's directors also sit on 32 other boards. 32 are in the same sector.
-
Bicara Therapeutics Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
Jade Biosciences Inc. Same sectorvia Eric Dobmeier, Peter Kolchinsky and Rajeev M. Shah
-
Parabilis Medicines Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
Septerna Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Climb Bio Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
PepGen Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Sionna Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Vor Biopharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Atara Biotherapeutics Inc. Same sectorvia Eric Dobmeier
-
BlossomHill Therapeutics Inc. Same sectorvia Sheila Gujrathi
-
Bolt Biotherapeutics Inc. Same sectorvia Sheila Gujrathi
-
Corbus Pharmaceuticals Holdings Inc. Same sectorvia Winston Kung
-
Orthofix Medical Inc. Same sectorvia Vickie L. Capps
-
Processa Pharmaceuticals Inc. Same sectorvia Sheila Gujrathi
-
Structure Therapeutics Inc. Same sectorvia Eric Dobmeier
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $557,052
- 11 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 31, 2026 | David Alan Campbell Director, Officer (President and CEO) | Gift | −123,840 | — | — |
| Jul 8, 2026 | David Alan Campbell Director, Officer (President and CEO) | Option exercise | +7,000 | $4.21 | $29,470 |
| Jun 11, 2026 | RA Capital Nexus Fund II, L.P. Director | Grant or award | +5,500 | — | — |
| Jun 11, 2026 | Jake Simson Director | Grant or award | +5,500 | — | — |
| Jun 11, 2026 | Winston Kung Director | Grant or award | +5,500 | — | — |
| Jun 11, 2026 | Natasha Hernday Director | Grant or award | +5,500 | — | — |
| Jun 11, 2026 | Eric Dobmeier Director | Grant or award | +5,500 | — | — |
| Jun 11, 2026 | Vickie L. Capps Director | Grant or award | +5,500 | — | — |
| Jun 11, 2026 | Ronald W. Barrett Director | Grant or award | +5,500 | — | — |
| Jun 2, 2026 | Doyle Janeen Noel Officer (Chief Corp. & Bus. Dev. Ofcr) | Open-market sale | −4,059 | $14.03 | $56,948 |
| May 11, 2026 | Dobek Maria Officer (Vice President, Accounting) | Open-market sale | −2,038 | $14.17 | $28,878 |
| Feb 2, 2026 | Go William Officer (Chief Medical Officer) | Grant or award | +44,000 | — | — |
| Jan 2, 2026 | Meyer Andrew Hollman Officer (Chief Business Officer) | Open-market sale | −1,879 | $13.73 | $25,799 |
| Jan 2, 2026 | DiRaimondo Thomas Officer (Chief Scientific Officer) | Open-market sale | −2,505 | $13.73 | $34,394 |
| Jan 2, 2026 | David Alan Campbell Director, Officer (President and CEO) | Open-market sale | −8,072 | $13.73 | $110,829 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Janux Therapeutics Inc.
Who is the CEO of Janux Therapeutics Inc.?
David Alan Campbell is Janux Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Janux Therapeutics Inc.'s board?
Janux Therapeutics Inc.'s board has 12 directors: Alana B. McNulty, David Alan Campbell, Eric Dobmeier, Jake Simson, Jay Lichter, Natasha Hernday, Peter Kolchinsky, Rajeev M. Shah, Ronald W. Barrett, Sheila Gujrathi and 2 others.
Are Janux Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Janux Therapeutics Inc. insiders made no open-market purchases and sold $557,052 of shares in 11 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="janux-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.